Skip to content
Cultural Foundation
Author:
Antharis Therapeutics
Lonza Issues Exclusive, Target-Specific License to Antharis Therapeutics to Advance Next-Generation Dual Payload ADCs for Gastrointestinal Cancers
June 15, 2026